| CASE STUDY >
A successful "joint" venture
Written by: Kateřina Zapletňuková
Photo by: Jan Vágner

Kateřina Dušková
|
A family business
used the know-how of two generations to create a medical company.
The firm has now become a global player among producers of food
supplements for joint regeneration.
IN 1991 Petr and Kateřina Duškovi decided to move
from the town of Louny in North Bohemia to Ústí nad Orlicí. Biochemists
by education, neither were satisfied with the jobs they had found
in a local firm. In an effort to change their fortunes, in 1992
they decided to set up their own company. Orling came into existence,
to a great extent, thanks to Kateřina Dušková's father, Professor
Milan Adam, a rheumatologist and biochemist who developed a food
supplement for joint regeneration based on collagen hydrolysate.
Orling currently processes about 150 tons of collagen hydrolysate
per year, while according to Dušková, all US companies combined
annually process about 600 tons. This makes the Czech firm the
largest manufacturer of such products in the world.
| |
Benchmark
- Exploiting scientific know-how
- Filling a gap on the market
- Targeted, cost-efficient advertising
- Using region-savvy distributors for export markets |
A clinical approach to business
The initial stages of Orling involved the firm taking a CZK 1 million
loan from Česká spořitelna, in order to purchase equipment and
raw materials. The bank agreed to provide the money thanks to
the generosity of the couple's business partners, who used their
family homes as collateral. The firm was founded by six partners,
but two of them left in 1995, leaving the current owners - Kateřina
and Petr Duškovi, Milan Adam and Eliška Jansová - to operate
the firm. "My husband and I had nothing but know-how," recalls
Dušková.
Dušková says that, according to doctors, about two million people
in the Czech Republic have problems with their joints - and many
patients never get to a doctor, in spite of the fact that these
problems can lead to invalidism. This accounts for the product's
immediate popularity among Czech customers - from the elderly to
sportsmen, who use Orling products as preventative medicine. Orling's
turnover reached CZK 3 million during the first year, and it took
the firm only 2-3 years to achieve current revenues amounting to
about CZK 100 million.
Orling's assortment comprises about 20 kinds of products, including
supplements for animals such as dogs and horses, and a wide price
range to accommodate different customers. The company is constantly
developing new products, and Dušková points out that one new product
may take up to two years in development alone. After that, another
year will typically pass while the State Health Committee decides
upon approval. Finally, production may last for about two months. "Some
products get updated or phased out. We try to introduce new ones
twice a year," says Dušková.
Honesty cures advertising
From the very beginning, the entrepreneurs decided that their product
should be distributed through pharmacies and not grocery chains.
During the first year they worked meticulously creating a name
for their product among average consumers as well as professionals.
The company's main marketing tool is advertisements in print
- from industry publications and lifestyle magazines to daily
newspapers. Orling also participates in exhibitions and seminars
for doctors, pharmacists, and other medical professionals.
The company owners dismissed radio and televisions commercials
as being too superficial. "We manufacture a product connected
with a health problem that requires some serious talk," explains
Dušková. Partially due to the lower costs associated with print
media, Orling invests only about 15% of its revenues into advertising,
and prepares all advertising materials itself, without cooperation
from any agencies. "We did not have a single good experience
with advertising agencies," says Dušková. "We realized
that our customers expect professional information, and all the
agencies reduced our advertisements to superficial praise of the
product," she adds.
Getting the product out there
In 1995 Orling bought its own building, which it reconstructed
twice to bring it in line with EU regulations. About two years
later, the company started exporting its goods. Now shipments
(mainly veterinarian products) to Ireland, Saudi Arabia, Russia,
Germany, and Italy account for about 7% of annual revenue.
Sales in foreign countries are carried out through exclusive
distributors, all of whom are locals who know the territory. "It
is necessary to have a partner who understands the product
and can introduce it to the given market properly," notes
Dušková, adding that in most cases distributors contacted Orling
themselves. The firm has even developed customized products
for special distribution - such as the product created for
racing camels, which was to be sold in Saudi Arabia.
This year Orling expects a great increase of exports, due to
the Czech Republic's entry into the European Union. "Membership
will make foreign markets much more accessible for us," says
Dušková, pointing out that Asian countries only recognize US-
and EU-made products. The businesswoman also expects that western
markets will become more accessible for her firm once the EU
recognizes the Czech Republic as a full-value member. This, however,
will take several years. "Western markets accept the Czech
Republic as a supplier of parts, but never final products - especially
medicine and food supplements. This needs to change," she
says.
| Force
majeure factors
Not everything has gone smoothly for Orling, due to circumstances
beyond the firm's control. In 2000, BSE cases were discovered
in the Czech Republic. Customers lost faith in any products
made from beef - and Orling's supplements are based on collagen
hydrolysate, which is derived from cow and pig hides. Consequently,
around that time sales decreased by about 20%. "This
was an artificially provoked hysteria, designed to eliminate
overproduction," says the firm's marketing and development
manager Kateřina Dušková. Competitors that import supplements
from Canada seized on the situation to promote their products,
which are based on substances not connected with beef. To
minimize the damage, Orling's management heightened PR activities,
publishing safety information about the firm's products in
magazines and newspapers. Pharmacists also received data
proving the products to be safe and beneficial. However,
the firm was unable to completely overcome the drop in demand.
|
|